Thursday, June 12th, 2008 Posted in skin health | No Comments »
CuraGen Corporation (Nasdaq: CRGN), a clinical-stage biopharmaceutical company focused on oncology, announced that its Phase II Trial evaluating CR011-vcMMAE for the treatment of patients with unresectable Stage ... Read more..